(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 24 June 2004 (24.06.2004)

(10) International Publication Number WO 2004/052351 A1

- (51) International Patent Classification7: 31/07, 31/353, 31/375
- A61K 31/01,
- (21) International Application Number:

PCT/EP2003/013665

- (22) International Filing Date: 4 December 2003 (04.12.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 02027244.9

6 December 2002 (06.12.2002)

- (71) Applicant (for all designated States except US): DSM IP ASSETS B.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BARELLA, Luca [CH/CH]; Hofstetterstrasse 3, CH-4054 Basel (CH). GORALCZYK, Regina [DE/DE]; Allmendweg 7, 79639 Grenzach-Wyhlen (DE). SILER, Ulrich [DE/DE]; Ruschbachstrasse 27, 79639 Grenzach-Wyhlen (DE). WERTZ, Karin [DE/DE]; Bahnhofstrasse 68 A, 79618 Rheinfelden (DE).

- (74) Agent: MÜLLER, Ingrid; Roche Vitamins Ltd., Patent Department (VMD), Wurmisweg 576, CH-4303 Kaiseraugst (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO. RU. SC. SD. SE. SG. SK. SL. SY, TJ. TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL USE OF LYCOPENE

(57) Abstract: Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-cancerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the secondary prevention of non-cancerous symptoms and/or pahtologies (i.e., the supplementation after a successful therapy for the prevention of the relapse), which are associated with, favored by or caused by androgen signalling or which are sensitive to a reduction of androgen signalling.



